Newsfeeds Archive - Page 38 of 56

1 minute read

Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders

January 12, 2:11 PM

Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.<

RVVTF

2 minute read

Cathie Wood Reacts To Atai’s Drastic Stock Plunge After Doomed Clinical Study Results

By Lara Goldstein

January 12, 12:20 PM

After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche

ATAI

3 minute read

In Canada And In Jamaica You Can Produce Psychedelics — With Contrasting Legal Differences

By Lara Goldstein

January 11, 5:50 PM

Red Light Holland Moves Full Speed Towards Canadian Controlled Drugs and Substances Dealer's License

NUGL

4 minute read

6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements

By Lara Goldstein

January 10, 4:53 PM

Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space.

BRAXF

4 minute read

Psyched: NY Discusses Regulations, MDMA For PTSD Aims For Legalization, Shrooms For Eating Disorders & More

By Lara Goldstein

January 10, 2:16 PM

Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's Senate Health Committee.

PSIL

3 minute read

Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans

By Lara Goldstein

January 9, 10:26 PM

It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year.

CYBN

1 minute read

atai Life Sciences’ Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges

By Lara Goldstein

January 6, 9:09 PM

Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.).

ATAI